Abstract
The development of artificial oxygen carriers has attracted considerable recent interest because of the increasing cost of collecting and processing blood, public concerns about the safety of blood products, complications from blood transfusions, military requirements for increased volumes of blood during military conflicts, and a decrease in the number of new donors. To overcome these problems, perfluorocarbon-based oxygen carriers as well as acellular-and cellular-type, hemoglobin-based oxygen carriers have been developed for use as artificial oxygen carriers. Despite their extensive evaluation, including formulation and pharmacology, they have not been extensively used in clinical settings. One of the reasons for this is that their pharmacokinetics have not been well characterized. Artificial oxygen carriers require not only an acceptable level of physicochemical activity, but also clinical efficacy, as reflected by their retention in the circulation, and the absence of measurable accumulation in the body, if unexpected adverse effects are to be avoided. In this review, the pharmacokinetic properties of artificial oxygen carriers are discussed, with a focus on recent developments of our research related to the pharmacokinetic properties a cellular type of hemoglobin-based oxygen carrier.
| Original language | English |
|---|---|
| Pages (from-to) | 362-373 |
| Number of pages | 12 |
| Journal | Drug Metabolism Reviews |
| Volume | 43 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2011 Aug 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Accelerated blood clearance phenomenon
- Artificial oxygen carrier
- Disposition
- Hemorrhagic shock
- Hepatic chronic cirrhosis
- Liposome
- Mononuclear phagocyte system
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells. / Taguchi, Kazuaki; Maruyama, Toru; Otagiri, Masaki.
In: Drug Metabolism Reviews, Vol. 43, No. 3, 01.08.2011, p. 362-373.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells
AU - Taguchi, Kazuaki
AU - Maruyama, Toru
AU - Otagiri, Masaki
PY - 2011/8/1
Y1 - 2011/8/1
N2 - The development of artificial oxygen carriers has attracted considerable recent interest because of the increasing cost of collecting and processing blood, public concerns about the safety of blood products, complications from blood transfusions, military requirements for increased volumes of blood during military conflicts, and a decrease in the number of new donors. To overcome these problems, perfluorocarbon-based oxygen carriers as well as acellular-and cellular-type, hemoglobin-based oxygen carriers have been developed for use as artificial oxygen carriers. Despite their extensive evaluation, including formulation and pharmacology, they have not been extensively used in clinical settings. One of the reasons for this is that their pharmacokinetics have not been well characterized. Artificial oxygen carriers require not only an acceptable level of physicochemical activity, but also clinical efficacy, as reflected by their retention in the circulation, and the absence of measurable accumulation in the body, if unexpected adverse effects are to be avoided. In this review, the pharmacokinetic properties of artificial oxygen carriers are discussed, with a focus on recent developments of our research related to the pharmacokinetic properties a cellular type of hemoglobin-based oxygen carrier.
AB - The development of artificial oxygen carriers has attracted considerable recent interest because of the increasing cost of collecting and processing blood, public concerns about the safety of blood products, complications from blood transfusions, military requirements for increased volumes of blood during military conflicts, and a decrease in the number of new donors. To overcome these problems, perfluorocarbon-based oxygen carriers as well as acellular-and cellular-type, hemoglobin-based oxygen carriers have been developed for use as artificial oxygen carriers. Despite their extensive evaluation, including formulation and pharmacology, they have not been extensively used in clinical settings. One of the reasons for this is that their pharmacokinetics have not been well characterized. Artificial oxygen carriers require not only an acceptable level of physicochemical activity, but also clinical efficacy, as reflected by their retention in the circulation, and the absence of measurable accumulation in the body, if unexpected adverse effects are to be avoided. In this review, the pharmacokinetic properties of artificial oxygen carriers are discussed, with a focus on recent developments of our research related to the pharmacokinetic properties a cellular type of hemoglobin-based oxygen carrier.
KW - Accelerated blood clearance phenomenon
KW - Artificial oxygen carrier
KW - Disposition
KW - Hemorrhagic shock
KW - Hepatic chronic cirrhosis
KW - Liposome
KW - Mononuclear phagocyte system
UR - http://www.scopus.com/inward/record.url?scp=79960738078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960738078&partnerID=8YFLogxK
U2 - 10.3109/03602532.2011.558094
DO - 10.3109/03602532.2011.558094
M3 - Review article
VL - 43
SP - 362
EP - 373
JO - Drug Metabolism Reviews
JF - Drug Metabolism Reviews
SN - 0360-2532
IS - 3
ER -